Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), which transforms standard 2D and 3D echocardiography and a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. It also provides VMS+ software, 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients. Ventripoint Diagnostics Ltd. is headquartered in Toronto, Canada.…
UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform
Ventripoint Diagnostics (CVE: VPT) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Medical Devices industry, part of the Healthcare sector.
The shares were at 0.0650 CAD on 20 November 2026, down 35.0% over 52 weeks. Its 52-week range is 0.0650 CAD to 0.1900 CAD, and it trades at the bottom of that range.
Its market capitalisation is 12.65M CAD.
Ventripoint Diagnostics reports return on equity of 77.7%.
Its debt exceeds its cash by 2.28M CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.